Document is current
Any future updates will be listed below
-
Authors
Akuta, Norio
Kogiso, Tomomi https://orcid.org/0000-0003-1248-4324
Ikejima, Kenichi
Otsuka, Motoyuki
Kawaguchi, Takumi
Kawanaka, Miwa
Takahashi, Hirokazu
Tamaki, Nobuharu
Nakagawa, Hayato
Hikita, Hayato
Fujii, Hideki
Yamaguchi, Kanji
Yoneda, Masato
Kon, Kazuyoshi
Uchiyama, Akira
Seko, Yuya
Sakane, Sadatsugu
Shigefuku, Ryuta
Fujiwara, Naoto
Iwaki, Michihiro
Kobayashi, Takashi
Adachi, Takuya
Takeuchi, Yasuto
Tsutsumi, Tsubasa
Nakano, Dan
Shibayama, Kaoru
Urata, Noriyo
Miyaaki, Hisamitsu
Kuroda, Hidekatsu
Koseki, Masahiro
Sone, Hirohito
Matsubayashi, Yasuhiro
Kakisaka, Keisuke
Takai, Atsushi
Notsumata, Kazuo
Seike, Masataka
Takei, Yoshiyuki
Takeyama, Yoshifumi
Eguchi, Susumu
Watanabe, Sumio
Isomoto, Hajime
Yotsuyanagi, Hiroshi
Itoi, Takao
Takehara, Tetsuo
Mochida, Satoshi
- License Information
-
More Information
Article History
Received: 21 February 2026
Accepted: 29 March 2026
First Online: 13 May 2026
Declarations
:
: Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript is listed as follows: (1) Personal remuneration (honoraria, consulting fees, advisory roles, etc.) AbbVie Inc.; Amgen Inc.; Astellas Pharma; AstraZeneca; ASKA Pharmaceutical; Chugai Pharmaceutical; EA Pharma; Eisai; Eli Lilly; Fujimoto Pharmaceutical; Gilead Sciences; GlaxoSmithKline; Janssen Pharmaceutical; Kowa; Madrigal Pharmaceuticals; Mitsubishi Tanabe Pharma; Nippon Boehringer Ingelheim; Novo Nordisk; Novartis; Otsuka Pharmaceutical; Sanofi; Sumitomo Pharma; Taisho Pharmaceutical; Toray Industries; Ultragenyx Pharmaceutical. (2) Institutional research funding or other support (commercial/academic cooperation). A2 Healthcare; Astellas Pharma; Fujirebio; Gilead Sciences; Hitachi; Japan Strategic Medical Administration Research Center (J-SMARC); JEOL; Kewpie; Kowa; Kracie Holdings; Miz; Nobel pharma; Novo Nordisk; Ohara Pharmaceutical Industries; Otsuka Pharmaceutical; Parexel International; Sysmex; Takeda Pharmaceutical Company.
